Inventisbio, Co., Ltd. Class ASSE: 688382

Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States

· Issued by Inventisbio, Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis